RA Capital Management is a Boston-based investment firm that pursues evidence-based investing across public and private healthcare, life sciences, and planetary health sectors. The firm supports the growth of innovative companies from seed to later-stage financings, focusing on drugs, medical devices, diagnostics, biotech services, and research tools. RA Capital combines a data-driven research platform, TechAtlas, with a collaborative investment approach and a healthcare incubator, Raven, to help management teams advance ideas from inception through development and commercialization. It frequently co-invests, takes board seats, and participates in follow-on financings, aiming to back ventures that improve patient outcomes and reduce costs. The firm emphasizes US and European opportunities, maintains a multi-stage investment scope, and is headquartered in Boston.

MassVentures is a Massachusetts-based venture capital firm founded in 1978 that provides seed and early-stage funding to high-growth startups. It supports ventures as they move from concept to commercialization and offers mentorship, strategic guidance, and access to industry connections to help build scalable businesses. The firm backs innovations across quantum computing, clean energy, artificial intelligence, biotechnology, advanced materials, advanced manufacturing, and robotics, and operates programs such as MV Capital, MV Accelerate, and MV Spinouts to fund companies, accelerate commercialization, and translate academic research into viable enterprises. By leveraging the Massachusetts innovation ecosystem, MassVentures aims to bolster entrepreneurs outside traditional hubs and foster sustained growth within the regional economy.

Atlas Venture is a Cambridge, Massachusetts-based biotechnology investment firm that partners with life science entrepreneurs to translate scientific discoveries into medicines. With more than 30 years of experience, the firm focuses on creating and building early-stage biotech companies, providing capital, mentorship, and strategic guidance to advance therapies from concept to clinic. Atlas Venture concentrates on biopharmaceuticals, therapeutics, and related life sciences technologies, seeking to lead and support companies through development milestones and to realize value through IPOs, acquisitions, or partnerships. The firm emphasizes collaboration with founders to build scalable businesses that address unmet medical needs and accelerate medical innovation.

Alumni Ventures is a venture capital firm headquartered in Manchester, New Hampshire, that expands access to venture investing for accredited individuals by co-investing with leading venture capital firms and enabling participation through various structures such as funds, syndicates, and investment clubs. It collaborates with top firms including Andreessen Horowitz, Sequoia, and Y Combinator and supports opportunities across pre-seed to growth stages, across multiple sectors and geographies. The firm emphasizes rigorous due diligence, transparency, and diversification, leveraging a broad network of alumni investors and partners to connect founders with strategic capital and resources. With a global footprint and active involvement in the venture ecosystem, Alumni Ventures aims to broaden participation in venture capital while maintaining disciplined, founder-friendly investing.

Morningside Group is a Boston-area venture capital firm founded in 1986 as a family office for the Chan family. It makes long-term investments in companies applying novel science and technology, with expertise in life sciences, digital health, AI, materials, and technology, and a commitment to ethical business practices. The firm supports education, research, and healthcare through charitable initiatives with partners including Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and MIT Morningside Academy for Design.

General Catalyst is a venture capital firm that backs technology-driven companies across stages, providing early-stage and growth equity investments, capital, and strategic guidance to help startups scale. Founded in 2000, it emphasizes resilience and applied AI, supporting entrepreneurs across healthcare, fintech, consumer technology, enterprise software, and other sectors. The firm aims to accelerate growth by pairing portfolio companies with experienced mentors and networks, operating globally from multiple offices and managing substantial assets to support scale.

Flagship Pioneering is a Cambridge, Massachusetts–based venture capital firm that conceives, creates, resources, and grows first‑in‑category companies to transform human health, biology, medicine, energy, and agriculture. It combines scientific capacity with entrepreneurial leadership and capital management to systematically build ventures from science, pursuing seemingly unreasonable ideas toward transformational outcomes through an evolutionary approach. The firm fosters a culture of exploration to invent medicines, intelligence solutions, and preemptive health strategies, alongside innovations in agriculture. Its portfolio includes Moderna, Tessera Therapeutics, Generate:Biomedicines, Inari Agriculture, Quotient Therapeutics, and Lila Sciences, and it collaborates with industry and research partners to accelerate innovation with companies and institutions such as AWS, Pfizer, GSK, IQVIA, and Thermo Fisher.

OrbiMed is a global healthcare investment firm focused on supporting the development of therapies, medical devices, diagnostics, and health IT. Established in 1989, it manages a broad investment platform across venture capital, private equity, and public equity, targeting opportunities from early-stage startups to mature companies. The firm backs companies across biopharmaceuticals, biotechnology, life sciences, and digital health, providing financing and strategic resources to accelerate innovation. With a multinational presence and offices in New York, San Francisco, Mumbai, Herzliya, Shanghai, and beyond, OrbiMed pursues a diversified portfolio of healthcare companies worldwide.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on early-stage, technology- and science-driven startups, with a strong emphasis on life sciences, biotechnology, pharmaceuticals, healthcare, and related fields. The firm partners with scientists and entrepreneurs to bring academic innovations to market, offering strategic guidance, a deep network, and hands-on involvement beyond capital. It has funded and helped commercialize technologies developed at universities and national laboratories, and maintains a national and international investing footprint with offices in Chicago and Seattle. ARCH has raised multiple funds totaling over three billion dollars and backed more than 150 companies in the venture rounds, reflecting a track record of catalyzing discoveries and building durable companies in science sectors.

Invus is a global investment firm established in 1985 that partners with owner-led and growth companies to create lasting value. It emphasizes long-term relationships, aligns incentives with management, and provides capital and strategic guidance through a flexible structure that supports a wide range of situations. The firm manages multi-billion-dollar evergreen capital and operates from offices in New York, London, Paris, and Hong Kong.

Mission BioCapital is a life science venture capital firm that provides early-stage capital and hands-on support to founders from concept through clinical development. Its leadership team has a long history of collaboration and a track record of launching dozens of early-stage life science ventures, and the firm is known for its deep technical expertise and active, founder-friendly mentorship. With offices in San Francisco and Cambridge, Massachusetts, Mission BioCapital operates in regions rich in research, discovery, and venture activity. The firm offers programs such as the Platinum Program, which provides up to $500,000 in funding, lab space, mentorship, and access to drug discovery, legal, and financial services. It collaborates with corporate and strategic partners to accelerate development and help translate scientific discoveries into therapies, including relationships with AbbVie and Ono Venture Investment. Founded in 2009, Mission BioCapital focuses on early-stage life sciences and biotechnology companies and emphasizes collaboration, innovation, and support for founders to address unmet medical needs.

Founder Collective is a venture capital firm that backs seed and early-stage technology startups across sectors, with a focus on founder alignment, capital efficiency, and a long-term partnership approach. It supports companies from idea stage through IPO, emphasizing authentic founder–investor relationships, intrinsic value, and pragmatic, stage-focused investing. The firm is headquartered in Cambridge, Massachusetts, with offices in Boston and New York City, including the SoHo area, and operates across the United States and beyond. Founded in 2009 by a group of successful entrepreneurs, it is led by general partners Micah Rosenbloom, Amanda Herson, and David Frankel.

New Enterprise Associates is a venture capital firm founded in 1977 and headquartered in Menlo Park, California. It provides funding and hands-on support to technology and healthcare startups across stages, from seed to growth and IPO. The firm partners with founders to address technical challenges, guide product development, and expand markets, offering domain expertise and long-term collaboration. Its investment focus spans software, consumer technology, medical devices, healthcare technology, life sciences, artificial intelligence, and related sectors across the United States, Asia, and other regions. NEA emphasizes enduring relationships and collaborates closely with portfolio companies to build transformational businesses.

Third Rock Ventures is a Boston-based venture capital firm that concentrates on early-stage investments in life sciences and healthcare. It backs biotechnology, pharmaceuticals, medical devices, diagnostics, and related information technology companies with high growth potential, providing substantial initial capital and active support to accelerate development and commercial success. The firm emphasizes strategic collaborations and seeks meaningful involvement in portfolio companies, including potential leadership roles, to advance medicines, therapies, and diagnostics. By positioning its investments within the U.S. life sciences landscape, Third Rock Ventures aims to help startups translate scientific breakthroughs into clinically meaningful products and outcomes.

Accomplice is an early-stage venture capital firm headquartered in Cambridge, Massachusetts. It invests in technology startups across cybersecurity, esports, data analytics, SMB software, emerging hardware platforms, and marketplaces. The firm employs a community-driven approach, leveraging networks and platforms such as AngelList, Boston Syndicates, Maiden Lane, Spearhead, BOSS, Rev, and TUGG to identify and back founders. While the majority of its investments are in the Boston area, the portfolio spans the United States, Canada, and Europe. Formerly part of Atlas Venture, the technology group was renamed Accomplice in 2014 as the firm refined its focus on early-stage technology companies.

SOSV is a global venture capital firm headquartered in Princeton, New Jersey, that backs deep-tech startups across seed to growth stages with emphasis on human and planetary health. It provides founders with labs, offices, expert teams, mentorship, investor networks, and accelerator-style programs to accelerate product development, testing, commercialization, and fundraising. SOSV operates three deep-tech facilities, including SOSV SF & NY (IndieBio) and HAX in Newark, and supports a portfolio of more than 800 companies across 58 countries. The firm has a broad global footprint with offices in San Francisco, New York, Newark, and Princeton, has raised over 7.5 billion for its portfolio, and makes approximately 60 pre-seed investments annually alongside many follow-on rounds. It seeks co-investors and limited partners to join its network, and pursues cross-border opportunities, notably in Asia, to accelerate growth and fundraising for its startups.

Casdin Capital is a New York-based venture capital firm founded in 2012 by Eli Casdin. The firm focuses on life sciences and healthcare, including biotechnology, oncology, digital health, agtech, and related areas, and invests in private companies across stages from early to late, seeking opportunities that leverage data analysis, genomics, and precision medicine. It emphasizes partnerships with experienced teams and maintains a long-term investment horizon, and applies its data expertise to inform investment decisions while upholding ethical considerations in the industry.

Hyperplane Venture Capital is a Boston-based early-stage technology investment firm that backs exceptional founders building machine intelligence and data-driven companies. The firm concentrates on startups leveraging artificial intelligence, machine learning, sensor technology, cloud computing, automation, robotics, and related areas, seeking solutions at the intersection of perception, communication, intelligence, and insight. It often makes early checks and emphasizes long-term partnerships to help portfolio companies scale from inception toward enduring market impact. Portfolio focus includes AI-enabled infrastructure, autonomous systems, robotics, secure collaboration, supply chain visibility, and other AI-powered workflows across diverse industries. The firm partners with founders to shape solutions and build durable, iconic businesses where AI intersects with real-world workflows and infrastructure.

Spark Capital is a venture capital firm founded in 2005 with offices in San Francisco, Boston, and New York City. It provides early-stage and growth funding to startups across sectors including consumer, software, fintech, media, and internet services. The firm emphasizes a founder-friendly, collaborative approach and seeks to back ambitious teams that aim to reshape markets. Its portfolio includes notable companies such as Twitter, Discord, Oculus, Warby Parker, and Tumblr, illustrating a track record of supporting product-driven ventures across stages.

TCG Crossover is a science-driven healthcare investment firm focused on supporting the development of disruptive medicines. It invests in both private and public companies led by entrepreneurs pursuing better treatment options and maintains a portfolio aimed at advancing innovative pharmaceutical solutions. Based in Palo Alto, California, with investment teams in Palo Alto and New York City, the firm targets investments in the United States and Europe, emphasizing healthcare, digital health, and health technology sectors.

Deerfield Management is a New York–based healthcare investment firm focused on advancing health outcomes through investment, research, and philanthropy. It invests across public and private markets in biotechnology, pharmaceuticals, diagnostics, healthcare services, medical devices, and digital health, using flexible funding models and strategic partnerships to support companies at various stages and to foster innovation. The firm operates an internal research and development engine to accelerate discovery and development, and maintains a philanthropic foundation that funds education, healthcare access, and initiatives to improve health outcomes. Through collaboration with strategic partners and a commitment to data-driven insights, Deerfield Management seeks to advance healthcare technology and services while building a broader, sustainable health ecosystem.

.406 Ventures is a Boston-based venture capital firm that focuses on early-stage investments in information technology, security and infrastructure, software, and technology-enabled business services, with a strong emphasis on cybersecurity, cloud software, digital health, data analytics, fintech, AI and big data. The firm primarily backs B2B and enterprise IT companies and often acts as lead or first institutional investor, seeking to partner with founders to scale growth. It targets companies in the Northeast United States, beginning with initial commitments typically between $2 million and $5 million and total investments between $6 million and $10 million per company, with follow-on support as the company grows. The team emphasizes hands-on involvement, leveraging deep industry experience and networks to help portfolio companies succeed, including board representation. Founded in 2005 and headquartered in Boston, the firm combines operational know-how with capital to create value for entrepreneurs and investing partners.

Beacon Angels is a Boston-based angel investment group that backs early-stage, fast-growing companies in New England. It provides capital and strategic support to entrepreneurs, with regular monthly meetings to review opportunities. Membership is open to accredited investors seeking portfolio growth, and the group is a member of the Angel Capital Association.

Boston Seed Capital is a venture capital firm based in the Boston area, with a Wellesley Hills, Massachusetts office, that provides seed- and early-stage funding to internet-enabled startups across the United States. It focuses on consumer goods, business services, and technology, including information technology, SaaS, cybersecurity, e-commerce, big data, marketplaces, artificial intelligence and machine learning, and esports. The firm adopts a hands-on, founder-focused approach, collaborating with entrepreneurs from concept through scale, drawing on experience in supporting both consumer and business-to-business software ventures. Founded in 2010, it aims to help early-stage companies grow in a competitive technology landscape.

Safar Partners is a venture capital investment firm based in Cambridge, Massachusetts, founded in 2018. It funds technology companies at seed to growth stages in sectors including cleantech, advanced materials, artificial intelligence and information technology, robotics, and life sciences. The firm sources opportunities through deep relationships with leading universities such as MIT, Harvard, and the University of Rochester, and provides guidance to portfolio companies as they scale. Safar Partners operates as a registered investment adviser and emphasizes applying ESG considerations within its investment approach.

Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland, with additional offices in San Francisco and Cambridge. The firm focuses on investing in life sciences, diagnostics, digital health, health technology, AI and machine learning, and related technology sectors, supporting breakthrough science and technology-driven companies from early to growth stages. Its portfolio targets companies that aim to deliver meaningful advances in healthcare and technology, and the firm emphasizes building a better tomorrow through strategic capital and resources that help entrepreneurs develop and scale impactful solutions across life sciences, technology and affiliated industries.

Launchpad Venture Group is a Boston-based angel investor network that provides financial and human capital to early-stage science and technology startups. Founded in 2001, it supports ventures across software, information technology, web and mobile sectors, medical devices and diagnostics, healthcare IT, networking and telecom, and clean-tech and renewable energy, with a focus on U.S. opportunities in New England. The group emphasizes mentorship alongside funding, seeking to build long-term relationships with innovative founders. Through its network, Launchpad Venture Group connects portfolio companies to potential customers, service providers, partners, and future sources of financing. It has invested more than $125 million in over 150 startups, aiming to help entrepreneurs scale and succeed.

Pillar VC is an early-stage venture capital firm based in Boston, founded in 2016 by a group of CEOs who have built successful companies. It backs technically driven founders across artificial intelligence, biotechnology and deep tech from inception, partnering with teams to accelerate breakthrough technologies. The firm manages substantial capital, including around 500 million in assets and a 175 million Fund IV, and has invested in roughly 90 companies, about half with university roots. Notable portfolio companies include Wayfair, Ginkgo Bioworks, DraftKings, Abridge, ButcherBox and Flywire.

MPM BioImpact is a venture capital firm based in Boston that invests in biotechnology, healthcare, and life sciences companies across the entire drug development process, from early research to public markets. With over 30 years of experience, the firm backs private and public companies aiming to translate scientific breakthroughs into life-saving medicines. It emphasizes building and supporting ventures that improve patient outcomes, drawing on a team of industry experts and entrepreneur partners. Its portfolio includes Orna Therapeutics, developing circular RNA medicines, Aktis Oncology, pioneering radio-pharmaceuticals, and Reunion Neuroscience, advancing psychedelic-inspired therapies for mental health. MPM BioImpact has demonstrated a track record of backing companies that produce FDA-approved drugs, engage in M&A activity, and pursue initial public offerings, reflecting a continued commitment to advancing innovative therapies.

CRV is a Palo Alto–based early-stage venture capital firm that traces its roots to 1970 as Charles River Ventures. The firm pursues a hands-on, value-added approach to back seed through Series B technology, consumer, healthcare and enterprise companies across North America. With a long history as one of the industry’s oldest venture firms, CRV emphasizes deep collaboration with founders, mentorship on strategy, product development, customer acquisition and IP protection to help portfolio companies reach growth milestones. It maintains offices in Cambridge, Massachusetts, and Menlo Park, California, and has supported a broad set of startups that have gone on to become category leaders. CRV aims to act as a trusted, long-term partner beyond capital, guiding companies from inception to IPO and beyond.

Prelude Ventures is a venture capital firm based in San Francisco, California that funds early-stage startups developing solutions to mitigate climate change. The firm targets a broad range of sectors, including the built environment, carbon management, compute, energy, food and agriculture, manufacturing and industrials, and mobility, aiming to support category-defining companies at their earliest stages. By aligning investment with climate impact, Prelude Ventures seeks to accelerate innovation and foster impactful technologies that address climate challenges.

Khosla Ventures is a California-based venture capital firm that invests in technology companies across stages, with a focus on artificial intelligence, healthcare, sustainability, climate tech, digital health, and consumer technology. Based in Menlo Park, the firm seeks startups with innovative technologies or business models and provides strategic guidance to help build lasting companies, offering active support to founders to accelerate growth and scale in both early- and later-stage opportunities.

E14 Fund is a Cambridge, Massachusetts-based venture capital firm that concentrates on seed and early-stage investments in deep technology companies, with a particular focus on startups originating from MIT. It supports portfolio companies from pre-seed to Series A, helping translate academic research into commercial products and scale technologies for real-world impact. Leveraging a broad network of advisors, industry experts, and entrepreneurs, it assists portfolio firms with strategy, fundraising, and market development. The firm backs ventures across sectors such as artificial intelligence, robotics, biotechnology, smart cities, and manufacturing, and aims to build inclusive communities by partnering with diverse founders. E14 Fund positions itself as an early partner that connects founders with resources and opportunities within its ecosystem.

G20 Ventures is a venture capital firm based in Cambridge and Boston, Massachusetts, that provides early traction capital to East Coast enterprise technology startups. It focuses on early-stage investments in enterprise software and related infrastructure, including virtual infrastructure and cloud-based solutions, with a preference for technology risk over market risk. The firm typically targets Series A rounds, with a sweet spot of 2 to 5 million, and reserves capital for earlier-stage deals to remain involved. It emphasizes a collaborative, community-driven approach, combining capital with storytelling and industry connections to help founders scale. G20 Ventures seeks teams with a core duo including a technologist and a business leader, a product in market, and early customer validation, and it operates within the Boston area as part of a broader Northeast ecosystem.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. As a venture capital investor and registered investment adviser, it partners with entrepreneurs developing novel medicines and life-saving therapeutics, supporting discovery and development through long-term collaborations. The firm emphasizes a molecular understanding of biology and chemistry to identify promising opportunities with potential patient impact, investing across early-stage and later-stage biotech companies. It backs innovative ventures addressing unmet medical needs and aims to accelerate translational research to bring transformative therapeutics to patients.

Samsara BioCapital is a biotechnology-focused venture capital firm based in Palo Alto, California, established in 2016. The firm concentrates on funding and supporting biotechnology companies and transformative therapeutics across the United States, leveraging multidisciplinary expertise and strategic partnerships to accelerate clinical and commercial breakthroughs. As a registered investment adviser, Samsara BioCapital combines scientific insight with strategic resources to help entrepreneurs advance innovative medicines.

CVP Management is a venture capital firm focused on early‑stage technology investments, including seed and early Series A rounds. It concentrates on information technology infrastructure with emphasis on software applications, internet, digital media, digital marketing, vertical SaaS, cloud, embedded software, mobile, and financial services technologies. The firm typically invests from $0.1 million to $1 million, and for seed and Series A rounds from $1 million to $3.5 million, in companies with an enterprise value around $5 million. It prefers to hold a seat on the portfolio company board and to invest in preferred stock. The firm funds companies located in the Northeast corridor, especially Boston, New York, and Toronto, and began operation on June 1, 1998, with headquarters in Cambridge, Massachusetts, and an additional office in Boston.

Boxer Capital is a biotechnology investment firm that serves as the corporate venture capital arm of Tavistock Group. Based in the United States, the firm invests in public and private biotechnology and life sciences companies across the drug development lifecycle, from early discovery to commercial stage, with a focus on precision medicine and transformative medical advancements. Boxer Capital combines fundamental research with a multidisciplinary analysis of scientific, clinical, regulatory, and commercial factors to translate innovation into opportunity. It pursues opportunities across the full drug lifecycle and provides financial capital and strategic guidance to portfolio companies. The firm notes partnerships with companies such as Mirati Therapeutics and Pandion Therapeutics as examples of its collaborative approach.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on technology and healthcare, investing in seed and early-stage companies as well as growth opportunities, and has backed influential firms such as Apple Computer, Intel, Illumina, Nest, and SlideShare. The firm supports portfolio companies across information technology, life sciences, software, cybersecurity, and emerging technologies, pursuing disruptive innovations and long-term growth through partnerships with entrepreneurs to build enduring companies.

Right Side Capital Management is a San Francisco-based venture capital firm that targets early-stage, capital-efficient technology startups. Using a quantitative, data-driven approach, it makes rapid funding decisions for companies that are pre-product-market fit or early in their development, often with small rounds and modest valuations. The firm emphasizes speed and transparency, typically delivering a yes or no decision within weeks, and it seeks to build ultra-diversified portfolios across many portfolio companies. Beyond capital, it provides substantial post-investment mentorship and operational support, including guidance on sales and marketing and other growth functions, leveraging the founders' decades of tech experience and an expansive network. Investments span the United States and Canada, with activity focused on technology-enabled companies across these markets. Since its founding in 2012, Right Side Capital positions itself as funding startups that are underserved by traditional professional investors, operating like an operating company rather than a conventional VC and aiming to help founders accelerate fundraising and scale their ventures.

Sigma Partners was a venture capital firm founded in 1984 and originally based in Campbell, California, with additional offices in Boston, Menlo Park and San Ramon. The firm specialized in early- and mid-stage investments across sectors including semiconductors, mobile computing, electronics, infrastructure, internet and software. It favored opportunities in Canada and the United States and managed more than two billion dollars at its peak. The firm has since split into two entities: Sigma West, which is now Jackson Square Ventures, and Sigma Prime Ventures. Through its history, Sigma Partners supported a range of startups before the split, contributing capital and guidance to accelerate growth.

Omega Funds operates as a Boston-based venture capital investment firm focused on early-stage life sciences and healthcare opportunities in North America and Western Europe. It backs companies across biotechnology, pharmaceuticals, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and SaaS, and manages multiple venture funds including Omega Fund IV, V, VI, and VII. With offices in Boston and Geneva, Omega Funds collaborates with researchers and entrepreneurs to advance medical innovations and bring new therapies and products to patients, pursuing value through strategic support, potential exits, and long-term partnerships.

Boston Harbor Angels is an angel investment group based in Boston, formed in 2004. It is composed of proven business leaders who invest a portion of their assets in high-growth early-stage companies. They operate as individual investors who collaborate in due diligence and occasionally take a lead role, especially in life sciences, though they are open to other opportunities. They are not a fund; each member makes an independent investment decision. They typically target early-stage opportunities seeking about 250,000 to 1.5 million in funding and favor capital-efficient businesses that can reach profitability with less than 5 million in equity investment and aim for at least a 10x return within five years. The group evaluates about 20–30 business summaries per month, invites eight to present, and narrows to four for due diligence before investing. Their sector focus spans information technology, life sciences, fintech, healthcare, consumer products, and other technology-driven industries. Boris Batchvarov serves as managing director and oversees day-to-day operations.

Longwood Fund is a Boston-based venture capital firm that backs science-driven healthcare and life sciences companies. Founded in 2010, it targets solutions for serious medical problems and often collaborates with technology originating from leading labs such as Harvard and MIT. The firm positions itself as a value-add investor, working closely with portfolio companies to translate research into patient therapies, with partners actively engaging as co-founders or senior executives when appropriate. Its focus spans healthcare, pharmaceuticals, biotechnology, and oncology, aiming to accelerate the journey from lab discovery to clinical impact.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 by John Diekman and Andrew Schwab. It focuses on seed- and early-stage investments in life sciences and healthcare, including biopharmaceuticals, medical technology, and related research instruments, with activities across the United States and an office in Boston. The firm backs companies developing innovative medicines and life science tools, aiming to advance therapies and diagnostic technologies through hands-on partnership with founders.

Refactor Capital is a Burlingame, California-based venture capital firm that makes seed-stage investments in hard-tech and biotechnology startups across the United States. Led by solo general partner Zal Bilimoria, the firm typically writes early checks in the range of $1–$2 million. It backs founders developing transformative technologies across sectors such as artificial intelligence, infrastructure, applied biology, energy, aerospace, earth systems, manufacturing, and critical materials. Its portfolio includes Solugen, Astranis, and Coinbase. Refactor Capital aims to be the first investment source for promising startups, focusing on backing founders who refactor the real world.

Arkin Capital is an Israeli investment firm based in Herzliya that operates a multi-asset platform spanning venture capital, private equity, and hedge funds. With an AUM of over $2 billion, it pursues opportunities across life sciences, biotechnology, digital health, cybersecurity, fintech, and real estate, deploying capital through four main arms: Arkin Health, Arkin Equity, Arkin Tech, and Arkin Real Estate. The firm has a global reach, investing in Israel, North America, and Europe, and has backed more than 100 companies with multiple exits, reflecting a hands-on approach to supporting entrepreneurs and growth-stage companies worldwide.

The Dementia Discovery Fund is a global venture capital initiative focused on financing companies developing novel therapeutics and enabling technologies for dementia. It leverages a broad network of venture partners, scientists, entrepreneurs, and strategic collaborators to identify, fund, and develop biotech ventures that advance dementia research and treatment. With offices in London and Boston, the initiative mobilizes capital and expertise to accelerate scientific progress and seeks meaningful patient impact alongside financial returns. It is supported by a diverse base of partners from the pharmaceutical industry and philanthropic organizations.

Deep Track Capital is a Greenwich, Connecticut-based venture capital firm focused on the biotechnology and life sciences sectors. It invests in public and pre-IPO biotechnology companies and emphasizes partnering with management teams, offering time, expertise, and a broad network in addition to capital. The firm aims to lead transactions, form large syndicates, and participate in rounds led by other qualified investors, providing strategic guidance and resources to portfolio companies.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. It operates a multi-strategy platform spanning venture capital, private equity including buyouts, growth equity, and public equity, and invests across biopharmaceuticals, specialty pharmaceuticals, medical devices, diagnostics, and healthcare services. The firm backs hundreds of companies worldwide, with a focus on the United States and China, and maintains a track record of portfolio exits through initial public offerings and mergers and acquisitions. Its team comprises physicians, scientists, entrepreneurs, operating executives, and industry experts who collaborate to build high-quality healthcare companies and advance patient outcomes. Reported assets under management are approximately six billion dollars.